The Institute of Biophysics and Cell Engineering offers pooled mesenchymal stem cells obtained from adipose tissue or olfactory lining of at least three donors to consumers under a manufacturing agreement and is looking for partners to conclude a distribution services agreement.

The composition of the biomedical cell product (BMCP) includes a pooled (combined) culture of mesenchymal stem cells (MSCs) obtained from adipose tissue or olfactory lining of at least three donors.

This approach to obtaining BMCP from different donors allows:

– to achieve stable immunofunctional properties of a mixed culture,

- optimize and reduce the cost of the production process,

— to drastically reduce the time of obtaining and accumulating a therapeutically significant biomass of MSCs, which opens up the possibility for cell therapy of acute diseases.

The registration certificate of the Ministry of Health of the Republic of Belarus can be viewed here (in Russian).

(in Russian).
Price list for biomedical cell products for foreign citizens (RU) can be downloaded here (in Russian).

The composition of the biomedical cell product (BMCP) includes a pooled (combined) culture of mesenchymal stem cells (MSCs) obtained from adipose tissue or olfactory lining of at least three donors.

Pooled cultures of allogeneic MSCs (poolMSCs) have more pronounced and stable immunomodulatory properties compared to MSCs obtained from a single donor. Due to proven immunomodulatory, cytoprotective and regenerative effects, as well as safety and good tolerability, poolMSCs have great clinical potential, especially in the treatment of autoimmune diseases. The low immunogenicity of pooled MSCs makes it possible to use BMCPs based on them without selecting a donor-recipient pair.

Directions of fundamental and applied scientific researches of researches of the Institute.

In the field of medical biotechnology:
- genetic engineering - development of innovative biomedical cell products based on genetically modified cells;
- immunology and allergology - development of new methods of treatment and diagnosis of allergic diseases and immune dysfunctions;
- innovative vaccines - development of prototypes of domestic DNA and RNA vaccines for the prevention of viral diseases;
- new approaches to diagnostics - development of new technologies for early diagnosis of diseases and methods of personalized medicine aimed at improving the quality of human life;
- genome editing - somatic, induced pluripotent stem cells, which will allow to treat diseases, including orphan, genetic ones;
- synthetic morphogenesis - including engineering of tissues and organs.

In the field of bioinformatics technologies:
- structurally based design of new generation drugs, development of innovative targeted anticancer and antiviral drugs using structural bioinformatics methods;
- synthesis of targeted drugs and their testing under in vitro conditions.

In the field of nanotheranostics and personalized nanomedicine:
- development of means of targeted delivery of therapeutic drugs of a new generation using nanomaterials;
- development of biological nanochips for the diagnosis of diseases;
- study of biocompatible nanomaterials with a wide spectrum of action for the creation of biomedical cellular products, artificial organs, fundamentally new materials with antimicrobial, antiviral and anti-inflammatory activity.

Activities of the Center for Experimental and Applied Virology:
- cultivation of viruses, development of new methods of cultivation of human viruses to create diagnostic tools, medical prevention and treatment of viral diseases;
- creation of prototype vaccines - against influenza (inactivated and recombinant), against African swine fever (vector), against pulmonary tuberculosis (therapeutic based on donor dendritic cells), innovative drugs against influenza.

Over the past years, the Institute has been fulfilling a number of international contracts and agreements within the Framework Programs of the European Union, as well as with leading scientific centers, foundations, and societies.
Languages spoken

Consumers interested in purchasing pooled mesenchymal stem cells derived from adipose tissue or olfactory lining from at least three donors under a manufacturing agreement.

Partners interested in purchasing pooled mesenchymal stem cells derived from adipose tissue or olfactory lining from at least three donors under a distribution services agreement.